Related references
Note: Only part of the references are listed.Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up
Eva L. Kneepkens et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Pharmacokinetic study and Fcγ receptor gene analysis in two patients with rheumatoid arthritis controlled by low-dose infliximab
Shinichiro Nishio et al.
Modern Rheumatology (2014)
Anti-TNF Treatment Response in Rheumatoid Arthritis Patients Is Associated with Genetic Variation in the NLRP3-Inflammasome
Jacob Sode et al.
PLOS ONE (2014)
Functional FCGR3A 158 V/F and IL-6-174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis
Young Ho Lee et al.
RHEUMATOLOGY INTERNATIONAL (2014)
A novel specific pyrosequencing method for genotyping FCGR3A rs396991 without coamplification of homologous gene FCGR3B
Tahar van der Straaten et al.
PHARMACOGENETICS AND GENOMICS (2013)
The Role of Fcγ Receptor Polymorphisms in the Response to Anti-Tumor Necrosis Factor Therapy in Psoriasis A Pharmacogenetic Study
Marc Julia et al.
JAMA DERMATOLOGY (2013)
Anti-TNF therapy
Nishanthi Thalayasingam et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2011)
Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients
M. J. Morales-Lara et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2010)
Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to antitumour necrosis factor alpha therapy in rheumatoid arthritis
J. D. Canete et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
A polymorphism in the gene encoding the Fcγ IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis
S. Tsukahara et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Fcγ receptor type IIIA genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis
Alf Kastbom et al.
ARTHRITIS AND RHEUMATISM (2007)
Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents
Z Tutuncu et al.
ARTHRITIS AND RHEUMATISM (2005)
The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept
LA Criswell et al.
ARTHRITIS AND RHEUMATISM (2004)
Drug therapy - Therapeutic strategies for rheumatoid arthritis
JR O'Dell
NEW ENGLAND JOURNAL OF MEDICINE (2004)
IgG Fc receptor polymorphisms in human disease: Implications for intravenous immunoglobulin therapy
BA Binstadt et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
FcγR polymorphisms:: Implications for function, disease susceptibility and immunotherapy
NM van Sorge et al.
TISSUE ANTIGENS (2003)
Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients
WL van der Pol et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
Infliximab and methotrexate in the treatment of rheumatoid arthritis
PE Lipsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
A novel PCR-based method for direct Fcγ receptor IIIa (CD163) allotyping
FGJ Leppers-van de Straat et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
Share Paper
